ChemoCentryx, Inc. (NASDAQ:CCXI) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02, Bloomberg Earnings reports. The firm had revenue of $8.94 million for the quarter.

ChemoCentryx (NASDAQ CCXI) traded down 5.61% during trading on Thursday, hitting $7.41. 403,608 shares of the stock traded hands. ChemoCentryx has a 12 month low of $3.95 and a 12 month high of $10.80. The firm’s 50-day moving average is $9.63 and its 200-day moving average is $7.72. The stock’s market cap is $356.81 million.

In related news, insider Petrus Bekker sold 19,877 shares of the stock in a transaction on Monday, July 10th. The stock was sold at an average price of $9.30, for a total transaction of $184,856.10. Following the completion of the sale, the insider now directly owns 79,426 shares of the company’s stock, valued at $738,661.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 223,649 shares of company stock valued at $2,157,360. Corporate insiders own 26.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/chemocentryx-inc-nasdaqccxi-posts-quarterly-earnings-results-misses-estimates-by-0-02-eps/1469505.html.

CCXI has been the subject of several recent research reports. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a report on Tuesday. Finally, BidaskClub lowered shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Thursday.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Earnings History for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.